Akèy › Dematit atopik (Ekzema) › Texas
Etid klinik pou Dematit atopik (Ekzema) nan Texas
18 etid pou Dematit atopik (Ekzema) ap chèche patisipan nan sit nan Texas.
Vil nan Texas
Tèks ofisyèl etid la (Anglè)
Ph 1a/1b Single Ascending Dose and Multiple Ascending Dose Study of ARQ-234
- Clinical Site 102, College Station
- Clinical Site 104, San Antonio
Ap rekriteFaz 1Volontè an sante akeyi
Laj 18 a 65 · Tout sèks · Mizajou Sep 29, 2026 · NCT07453602This Study is a Non-interventional Disease Registry of Adolescent and Adult Patients With Atopic Dermatitis Who Initiate or Switch Any Systemic Treatment
- Reveal Research Institute - Dallas- Site Number : 8400012, Dallas
- Austin Institute for Clinical Research, Inc- Site Number : 8400030, Pflugerville
- Complete Dermatology - Sugar Land- Site Number : 8400001, Sugar Land
Ap rekriteEtid obsèvasyon
Laj 12 ak plis · Tout sèks · Mizajou Sep 29, 2026 · NCT07290803Platform Study to Evaluate the Efficacy and Safety of Investigational Compound(s) in Patients With Moderate to Severe Atopic Dermatitis
- Novartis Investigative Site, Arlington
- Novartis Investigative Site, Cypress
- Novartis Investigative Site, Dallas
- ak 2 plis
Ap rekriteFaz 2
Laj 18 a 100 · Tout sèks · Mizajou Sep 28, 2026 · NCT06947993Study of ENV-294 in Adults With Moderate-to-Severe Atopic Dermatitis
- Enveda Investigative Site, Arlington
- Enveda Investigative Site, Houston
- Enveda Investigative Site, San Antonio
Ap rekriteFaz 2
Laj 18 a 75 · Tout sèks · Mizajou Sep 25, 2026 · NCT07298395First-in-Human Trial to Assess REGN20423 in Healthy Adult Participants and Adult Participants With Atopic Dermatitis
- Texas Dermatology and Laser Specialists, San Antonio
Ap rekriteFaz 1Volontè an sante akeyi
Laj 18 a 65 · Tout sèks · Mizajou Sep 25, 2026 · NCT07527923A Long-term Study of the Medicine Called Abrocitinib in Children Aged 2 Years and Older With Moderate to Severe Eczema
- Texas Dermatology and Laser Specialists, San Antonio
Ap rekriteFaz 3
Laj 2 a 11 · Tout sèks · Mizajou Sep 25, 2026 · NCT06807281A Long-term Safety and Efficacy Study Evaluating APG777 in Atopic Dermatitis
- Investigational Site, Dallas
- Investigational Site, Frisco
- Investigational Site, San Antonio
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Sep 23, 2026 · NCT07003425Evaluation of a Non-Invasive Device for Early Detection of Atopic Dermatitis Flares
- Harrison Dermatology, Missouri City
Ap rekriteEtid obsèvasyon
Laj 12 a 89 · Tout sèks · Mizajou Sep 15, 2026 · NCT07645820A Double-Blind, Randomized, Vehicle-Controlled Phase 2 Study to Assess the Efficacy and Safety of GX-03 in Adult Subjects With Moderate to Severe Atopic Dermatitis (Eczema)
- ALS Global, Irving
Ap rekriteFaz 2/3
Laj 18 a 80 · Tout sèks · Mizajou Sep 4, 2026 · NCT07355075A Phase 2b Study of the Effects of Camoteskimab in Adults With Moderate-to-Severe Atopic Dermatitis
- Progressive Clinical Research, PA, San Antonio
Ap rekriteFaz 2
Laj 18 a 65 · Tout sèks · Mizajou Aug 28, 2026 · NCT07599813A Study to Evaluate the Efficacy and Safety of IMG-007 in Adult Participants With Moderate-to-Severe Atopic Dermatitis
- Inmagene Site 8, Southlake
Ap rekriteFaz 2
Laj 18 a 74 · Tout sèks · Mizajou Aug 12, 2026 · NCT07037901A Phase 2b Dose-Ranging Study to Evaluate the Efficacy and Safety of ENV-294 in Adults With Moderate-to-Severe Atopic Dermatitis
- Enveda Investigative Site, Dallas
- Enveda Investigative Site, San Antonio
- Enveda Investigative Site, Sugar Land
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Aug 6, 2026 · NCT07643766A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis
- Arlington Research Center, Inc /ID# 266330, Arlington
- 3A Research - East location /ID# 267622, El Paso
- Prime Clinical Research - Mansfield - East Broad Street /ID# 268042, Mansfield
- ak 2 plis
Ap rekriteFaz 3
Laj 2 a 11 · Tout sèks · Mizajou Aug 6, 2026 · NCT06461897A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab
- Arlington Research Center, Inc /ID# 263665, Arlington
- Studies in Dermatology LLC /ID# 263335, Cypress
- Dermatology Treatment and Research Center /ID# 265812, Dallas
- ak 6 plis
Ap rekriteFaz 3
Laj 18 a 63 · Tout sèks · Mizajou Jul 6, 2026 · NCT06389136Evaluate Efficacy and Safety of Repeat Subcutaneous Doses of FB825 in Adults With Moderate-to-Severe Atopic Dermatitis
- UT Health Science Houston, Bellaire
- Center for Clinical Studies, Webster
Ap rekriteFaz 2
Laj 18 a 65 · Tout sèks · Mizajou Jun 15, 2026 · NCT06397911A Study To Learn About Two Study Medicines (PF-07275315 And PF-07264660) In People Who Have Moderate To Severe Atopic Dermatitis
- Dermatology Treatment and Research Center, Dallas
- North Texas Center for Clinical Research, Frisco
- DCT-Stone Oak, LLC dba Discovery Clinical Trials, San Antonio
- ak 1 plis
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou May 4, 2026 · NCT05995964Real-world Experience Using Nemolizumab in the Treatment of Moderate-to-Severe Atopic Dermatitis in Adolescents & Adults
- Galderma Investigational Site 7082, Cedar Park
- Galderma Investigational Site 8238, Dallas
- Galderma Investigational Site 7062, Edinburg
- ak 3 plis
Ap rekriteEtid obsèvasyon
Laj 12 ak plis · Tout sèks · Mizajou Mar 13, 2026 · NCT06988605Safety and Pharmacokinetics of LPX-TI641 in Atopic Dermatitis and Psoriasis
- Clinical Investigations of Texas, Dallas
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Dec 19, 2025 · NCT06982352Sous ClinicalTrials.gov, done yo ranmase Oct 3, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.